Joint research and development alliances with pharmaceutical companies and medical-device manufacturers
First written in FY2023. 6 of 10 entries say "Advanced", first in FY2025-H1. Latest entry: 2026-08-13.
0 other companies' latest entry also says "Restated".
- FY2026ReframedAnnual report
「The joint research and development agreement with DAIICHI SANKYO COMPANY,LIMITED. ended at the end of March 2026 because its purpose was achieved when Reheart obtained conditional and time-limited marketing approval in Japan in March 2026.」
The joint research and development relationship with DAIICHI SANKYO COMPANY,LIMITED. ended after approval was obtained. The alliance structure shifted to continuing and new collaborations including Stanford University, ASAHI INTECC CO.,LTD. and VMaCS. - FY2026-H1AdvancedAnnual report
「During the interim consolidated accounting period under review, we fully commenced joint research and development with Stanford University’s Division of Cardiothoracic Surgery. We are conducting a joint research program consisting of animal experiments involving transplantation into the hearts of pigs with myocardial infarction, with the aim of developing a product adapted from the existing human iPS cell-derived cardiomyocyte sheet for the U.S. market and products derived from human iPS cells based on new concepts.」
Joint research and development with Stanford University’s Division of Cardiothoracic Surgery began in earnest, and the company advanced to conducting an animal-experiment program using pigs with myocardial infarction for U.S.-adapted and new-concept products. - FY2025AdvancedAnnual report
「In December 2024, we entered into a joint research and development agreement with the Division of Cardiothoracic Surgery at Stanford University. Through this joint research, we aim to collect data for use in an application to the FDA for authorization to conduct a clinical trial and to conduct a clinical trial in the United States.」
In addition to existing collaborations with pharmaceutical companies and medical-device manufacturers, the company expanded into joint research and development with Stanford University for the U.S. market. - FY2025-H1AdvancedAnnual report
「The Group is participating in this consortium with manufacturing and quality-control technologies for iPS cell-derived regenerative medical products and proprietary design technologies for cell-culture processing facilities capable of mass production. Together with the participating companies, we will be among the first in the world to develop a platform system integrating the processes of culturing, harvesting, filling and dispensing, freezing and storage that constitute mass production of cells, as well as applications used in this system.」
In addition to individual alliances, the company established a consortium for development of a cell mass-manufacturing value chain at Nakanoshima Qross and expanded into integrated platform development with multiple companies. - FY2024RestatedAnnual report
「Joint research and development alliances with major pharmaceutical companies, medical-device manufacturers and others」
The policy of joint research and development with DAIICHI SANKYO COMPANY,LIMITED, ASAHI INTECC CO.,LTD., culture, equipment and information-management companies, and others, together with alliances for overseas expansion, continued. - FY2023First statedAnnual report
「Joint research and development alliances with major pharmaceutical companies, medical-device manufacturers and others」
The company is advancing cardiomyocyte-sheet research with DAIICHI SANKYO COMPANY,LIMITED, catheter research with ASAHI INTECC CO.,LTD., mass-culture research with Shikoku Instrumentation Co., Ltd., and joint development with facility-management companies, while also promoting alliances for overseas expansion.